Skip to content
Review

ACK family tyrosine kinases as potential therapeutic targets for cancer

Jul 2026 · Expert opinion on therapeutic targets · Vol 30, pp. 817 - 825 · 0 citations · 50 references
Medicine

TL;DR

This review comprehensively examines the ACK family architecture, regulation, epigenetic mechanisms, and roles in several malignancies and evaluates targeted therapies, immunotherapy, and drug development including selective inhibitors, dual agents, and rational combinations.

Abstract

ABSTRACT Introduction The activated Cdc42-associated kinase (ACK) family, comprising TNK1 and ACK1/TNK2, are critical regulators of oncogenic signaling and epigenetic reprogramming. Their unique structural architecture, including ubiquitin-association domain, sterile alpha motif domain, and Mig6 homology regions, distinguishes them from other non-receptor kinases. ACK1 often, elevated in diverse malignancies, functions as a cytoplasmic transducer and nuclear epigenetic modifier, phosphorylating histones H4 at Tyr88 and H3 at Tyr54 driving cell survival, therapy resistance, and immune evasion. Conversely, TNK1 predominantly operates via ubiquitin‑mediated signaling, P activation, and STAT-dependent pathways in hematological cancers. Hence, understanding these mechanisms is crucial for developing targeted therapeutic strategies. Areas covered This review comprehensively examines the ACK family architecture, regulation, epigenetic mechanisms, and roles in several malignancies. It evaluates targeted therapies, immunotherapy, and drug development including selective inhibitors, dual agents, and rational combinations. Expert opinion The unique structure of ACK kinases presents a distinct therapeutic target for selective inhibition. ACK1/TNK2 and TNK1 offer complementary opportunities whose parallel clinical development is scientifically justified and strategically timely. Future research should map the complete ACK family epigenetic framework for biomarker‑driven selection and deeper mechanistic understanding. Clinical development of selective ACK inhibitors will potentially provide new treatment options for difficult-to-treat malignancies.

View source

Similar papers

Review Oct 2026

RIPK1 kinase and scaffold activities in tumor cell fate and therapy.

Receptor-interacting protein kinase 1 (RIPK1) plays a pivotal role in regulating cell survival and death, thereby exerting complex and multifaceted functions in the initiation and progression of cancer. Its expression is frequently dysregulated across diverse malignancies and correlates strongly with poor prognosis, hi...

Jing-Yu Luo, Shu-Ya Song, Ze-Kun Li et al. · 0 citations
Review Open access Oct 2026

Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases

This review outlines BTK structure and signaling pathways, BTKi classification, resistance mechanisms, and emerging therapeutic strategies with emphasis on monotherapy in B‐cell malignancies and combination strategies involving CAR‐T therapy, immune checkpoint inhibitors, CD20‐targeted antibodies, BCL2 inhibitors, and...

Miao-Jing Sun, Deng-Ju Li, Jia Wei · 0 citations
Review Aug 2026

Molecular targeting of CDK9 in oncology therapeutics: avenues for translational impact.

The molecular functions of the CDK9/positive transcription elongation factor b (P-TEFb) axis, its role in super-enhancer-driven oncogenic programs, and the mechanisms by which CDK9 inhibition promotes apoptosis, epigenetic derepression, and tumor microenvironment remodeling are summarized.

Ti-Yao Liu, Zhongran Liu, Wen-Jing Wei et al. · 0 citations
Review Open access Sep 2026

Targeting MAPK Pathways in Skin, Thyroid, and Pancreatic Cancer: A Perspective on Synthetic Inhibitors and Natural Modulators

The findings presented in this review suggest that combining transcriptomic evidence with molecular and pharmacological analyses could aid target prioritization and accelerate the development of targeted strategies for MAPK‐driven malignancies.

Divya Wasnik, K. V. Swamy, Renu Vyas · 0 citations
Sep 2026

Integrative docking and molecular dynamics identify potential allosteric modulators of AKT1.

Competitive docking against the allosteric sites of AKT2 and AKT3 revealed a consistent preference for AKT1 across all three compounds, with a magnitude closely comparable to that of the reference allosteric ligand Inhibitor VIII, whose experimentally determined isoform rank order the protocol reproduced.

Raju Das, Armin Sultana, Kantu Das et al. · 0 citations
Review Open access Sep 2026

The SKP2–Substrate Axis in Hematological Malignancies: Mechanisms of Oncogenesis and Opportunities for Targeted Therapy

The biological functions of SKP2 and regulatory mechanisms governing its substrate spectrum across hematological malignancies, including acute myeloid leukemia, chronic myeloid leukemia, B/NK/T-cell lymphoma, and multiple myeloma are examined.

Yue-Ying Zhang, O. Faruq, M. Shrestha et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.